Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 8/20 | 0.55 |
| ▸ | HTR3A | P46098 | 9/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5649317 | 0.98 | CHRNA7 (0.53) | CHRNA7HTR3AGAASMN1; SMN2MEN1 | |
| SCHEMBL1542568 | 0.81 | HTR3A (0.46) | CHRNA7HTR3AGAASMN1; SMN2MEN1 | |
| SCHEMBL12005492 | 0.81 | CHRNA7 (0.46) | CHRNA7HTR3AGAASMN1; SMN2MEN1 | |
| SCHEMBL13444722 | 0.80 | CHRNA7 (0.59) | CHRNA7HTR3AGAA | |
| SCHEMBL3928547 | 0.80 | CHRNA7 (0.59) | CHRNA7HTR3AGAA | |
| Hydrochloric Acid SCHEMBL5649732 | 0.79 | HTR3A (0.44) | CHRNA7HTR3AGAASMN1; SMN2MEN1 | |
| SCHEMBL5407108 | 0.78 | CHRNA7 (0.54) | CHRNA7HTR3AGAAALOX15TSHR | |
| SCHEMBL5404570 | 0.77 | CHRNA7 (0.43) | CHRNA7HTR3AGAASMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL5652086 | 0.77 | CHRNA7 (0.52) | CHRNA7HTR3AGAASMN1; SMN2MEN1 | |
| SCHEMBL4961084 | 0.77 | HTR3A (0.56) | CHRNA7HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241773-B2 | 3-quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES (US) | 2007-07-10 | — | — | US | claimed |
| JP-2007515486-A | — | — | 2007-06-14 | — | — | JP | claimed |
| EP-1735305-A2 | 3-QUINUCLIDINYL HETEROATOM BRIDGED BIARYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2006-12-27 | — | — | EP | claimed |
| WO-2005066167-A2 | 3-QUINUCLIDINYL HETEROATOM BRIDGED BIARYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050137226-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | claimed |
| US-7241773-B2 | 3-quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1735305-A2 | 3-QUINUCLIDINYL HETEROATOM BRIDGED BIARYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005066167-A2 | 3-QUINUCLIDINYL HETEROATOM BRIDGED BIARYL DERIVATIVES | ABBOTT LABORATORIES (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050137226-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137226-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | CHRNA3, CHRNA1, CHRM3 | CHRNA7 11/4885HTR3A 71/4885GAA 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.